stockrow
Saturday 7 November 2026
Export GHRS’s income statement to Excel — free account
GH Research PLC
GHRS Healthcare Biotechnology
- EPS
- −53.3%
- Free cash flow
- −66.6%
- Total debt
- −97.9%
Quarter to June 2026, against a year earlier
18.49
0.05
+0.27%
Follow GHRS
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 3 | 3 | 3 | 0.0% | |
| Gross margin, % | — | — | — | — | — | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | — | — | 0 | 0 | (9) | (22) | (36) | (39) | (48) | (62) | +131.9% | ||||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | — | 0 | 0 | (9) | (22) | (36) | (39) | (48) | (62) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | 0.00 | (0.02) | (0.21) | (0.43) | (0.68) | (0.75) | (0.79) | (1.00) | +137.5% | ||||||
| Cash flow | — | — | — | 0.00 | (0.01) | (0.35) | (0.50) | (0.64) | (0.81) | (0.71) | (0.78) | +136.3% | ||||||
| Capex | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | 0.00 | (0.01) | (0.35) | (0.50) | (0.64) | (0.81) | (0.72) | (0.78) | +136.4% | ||||||
| Book value | — | — | — | 0.01 | 0.20 | 6.35 | 4.80 | 4.21 | 3.44 | 4.58 | 5.40 | +204.9% | ||||||
| Shares, m | — | — | — | 70 | 28 | 44 | 52 | 52 | 52 | 61 | 63 | (2.3%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | 0 | 0 | (15) | (26) | (33) | (42) | (44) | (52) | +130.7% | |||||
| Capex | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | +3.9% | ||||||
| Free cash flow | — | — | — | 0 | 0 | (15) | (26) | (33) | (42) | (44) | (52) | +130.8% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | 0 | 6 | 277 | 164 | 157 | 145 | 278 | 356 | +197.5% | |||||
| Net debt | — | — | — | 0 | (6) | (277) | (166) | (161) | (149) | (281) | (363) | +187.4% | ||||||
| Shareholders’ equity | — | — | — | 0 | 6 | 277 | 250 | 219 | 179 | 280 | 359 | +197.9% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | (123.02) | (13.90) | (6.44) | (8.41) | (14.81) | (18.80) | (20.26) | (18.16) | +102.8 pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | (2,365.29) | (22.77) | (44.39) | (104.83) | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | (10.34) | (14.70) | (6.51) | (8.52) | (15.18) | (19.58) | (21.04) | (18.79) | (10.7) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 8 | 14 | 32 | 49 | 50 | 73 | — | +55.6% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
GH Research PLC vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| TSHA Taysha Gene Therapies, Inc. | $1.3B | — (loss-making) | — (loss-making) | +206.77% (above 0%: growing) | n/m | −100.28% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| KARD KARDIGAN INC | $1.3B | — (loss-making) | — | — | n/m | — | — | 0.00% | Compare |
| GHRS GH Research PLC | $1.3B | — (loss-making) | — | — | n/m | −66.62% (below 0%: shrinking) | 0.00% | 0.00% | |
| URGN Urogen Pharma | $1.3B | — (loss-making) | — (loss-making) | +223.85% (above 0%: growing) | n/m | +63.95% (above 0%: growing) | 91.57% | 9.36% | Compare |
| OMER Omeros Corporation | $1.2B | 9.8× | 2.1× | +35.46% (above 0%: growing) | n/m | +118.70% (above 0%: growing) | 97.20% | 0.26% | Compare |
| DRTS Alpha Tau Medical Ltd. | $1.2B | — (loss-making) | — | — | n/m | −30.42% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| LBRX LB Pharmaceuticals Inc | $1.2B | — (loss-making) | — | — | n/m | −579.03% (below 0%: shrinking) | — | 0.00% | Compare |
| NKTR Nektar Therapeutics | $1.2B | — (loss-making) | — (loss-making) | −9.34% (below 0%: shrinking) | n/m | −65.73% (below 0%: shrinking) | 100.00% | (417.94%) | Compare |
| SLN Silence Therapeutics PLC Sponsored ADR | $1.2B | — (loss-making) | — (loss-making) | +197.18% (above 0%: growing) | n/m | +106.95% (above 0%: growing) | 97.39% | 0.00% | Compare |
| Median of peers | $1.2B | — | — | +197.18% | — | −30.42% | 97.30% | 0.00% |